Eculizumab
Pharmaceutical drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Eculizumab?
Summarize this article for a 10 year old
Eculizumab, sold under the brand name Soliris among others, is a recombinant humanized monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis, and neuromyelitis optica.[6][7] In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death.[9] Eculizumab was the first drug approved for each of its uses, and its approval was granted based on small trials.[10][11][12][13] It is given by intravenous infusion.[6]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | Complement protein C5 |
Clinical data | |
Trade names | Soliris |
Biosimilars | Bekemv,[1] Elizaria,[2] Epysqli[3] |
AHFS/Drugs.com | Monograph |
MedlinePlus | a612024 |
License data |
|
Pregnancy category |
|
Routes of administration | Intravenous |
Drug class | Complement inhibitor |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | 8 to 15 days (mean 11 days) |
Identifiers | |
CAS Number | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Molar mass | 148 kg/mol |
NY (what is this?) (verify) |
Side effects include a risk for meningococcal infections and it is only prescribed to those who have enrolled in and follow a risk evaluation and mitigation strategy, which involves counseling people and ensuring that they are vaccinated.[6][14] It is a humanized monoclonal antibody functioning as a terminal complement inhibitor.[11]
It is developed, manufactured, and marketed by Alexion Pharmaceuticals.[15]: 6